The Numbers Are Getting Ugly Fast

As of the most recent World Health Organization count, the DRC Bundibugyo outbreak stands at 1,041 total cases — 135 confirmed, 906 suspected — and 241 deaths. According to the Wall Street Journal, this is now the third-largest Ebola outbreak in history.

There is currently ZERO licensed vaccine or approved treatment that works against this specific strain.

Why Bundibugyo Is Different

Most people have heard of Ebola but don't realize there are multiple distinct virus species. According to WHO, the two licensed vaccines — Merck's Ervebo and Johnson & Johnson's Zabdeno/Mvabea — both target the Zaire strain. That's the one behind most major outbreaks, including the catastrophic 2014-2016 West Africa epidemic that killed over 11,000 people, as documented by Wellcome.

Bundibugyo is different. This is only the third outbreak ever caused by that strain. No vaccine made it through the finish line for it. No approved therapeutic exists. Health workers on the ground are operating without proven defenses.

CEPI Moves — $61.8 Million Across Three Bets

The Coalition for Epidemic Preparedness Innovations announced Monday it is "urgently accelerating" development of three vaccine candidates, according to Ars Technica.

The money breaks down as follows:

• $50 million to Moderna for preclinical work and Phase 1 clinical testing of its mRNA-based Bundibugyo vaccine candidate. The funding also covers manufacturing scale-up and readiness for Phase 2/3 trials if early results hold.
• $8.6 million to the University of Oxford and Serum Institute of India, using the same adenovirus platform Oxford used for its COVID-19 vaccine.
• $3.2 million to the International AIDS Vaccine Initiative, which is developing a candidate using technology similar to Merck's existing Ervebo vaccine.

Moderna CEO Stéphane Bancel said Monday: "We believe our mRNA platform can play an important role in responding rapidly to emerging infectious disease threats. We will move with urgency and scientific rigor."

The Hill confirmed the $50 million Moderna commitment. Ars Technica reported the full breakdown across all three recipients.

The mRNA Play

Moderna is getting the biggest check because of speed. The mRNA platform doesn't require growing live virus. It can be redesigned and manufactured faster than traditional vaccine approaches.

The Wellcome organization's historical record on the Zaire outbreak shows the contrast starkly — vaccine development for that strain took decades of slow progress before the 2014 epidemic forced a crash program. The world cannot afford to repeat that timeline with Bundibugyo.

Whether mRNA technology can actually deliver a safe and effective Bundibugyo vaccine fast enough to matter in this outbreak remains unclear. Phase 1 trials test safety and immune response, not efficacy. The jump to Phase 2/3 requires more time, more data, more money. A vaccine is not days away.

What Mainstream Coverage Is Getting Wrong

Most outlets are framing this as a feel-good "Moderna gets funding" story. The focus should be elsewhere.

The actual issue is failure of preparation. According to Ars Technica, detection of this outbreak was delayed — allowing the virus to spread before containment measures could kick in. The outbreak is burning through an area of DRC marked by armed conflict, high population movement, and ongoing humanitarian crisis. These are not minor details. They explain why 1,041 cases exist today.

The Bundibugyo strain has caused previous outbreaks. The absence of a licensed vaccine in 2026 is not some unforeseeable gap — it's the predictable result of global health funding that chases whatever strain just killed people and then moves on.

The NIH's own published research from the 2015 peer-reviewed journal Therapeutic Advances in Vaccines documented that over 15 Ebola vaccine candidates were in preclinical development as far back as that year. A decade later, the world still has nothing approved for two of the three major outbreak strains.

What This Means for Regular People

If you're not in the DRC, you're probably safe for now. Ebola spreads through direct contact with bodily fluids — it is NOT airborne. The qualifier "for now" carries significant weight.

This outbreak is in a high-traffic region with porous borders, active conflict zones, and overwhelmed health infrastructure. The WSJ flagged that case counts are "quickly climbing." At 1,041 cases with a significant number still suspected and unconfirmed, the true count could be higher.

The $61.8 million from CEPI is welcome. But it is reactive money chasing an outbreak already spiraling out of control. The harder question — why the world had no Bundibugyo vaccine ready after decades of warnings — goes largely unexamined in mainstream coverage.

Taxpayers in the US and Europe fund global health organizations precisely to prevent this kind of scramble. Whether they've been doing their jobs is an open question.